Longevity Therapies

The intervention classes under active research for extending healthspan: reprogramming, senescent-cell clearance, regenerative medicine, and gene therapy, with evidence levels noted for each.

Cellular Reprogramming

Using Yamanaka factors to partially or fully reset a cell's epigenetic age. Strong animal-study results; human safety data is still very limited.

Early-stage / research Epigenetic reprogramming

Gene Therapy

Modifying gene expression related to longevity pathways such as telomere maintenance, DNA repair, or mTOR signaling. Early and indication-specific, with no established longevity protocols yet.

Early / indication-specific Genetic intervention

mTOR Inhibition (Rapamycin)

Repurposing the decades-old immunosuppressant rapamycin at low doses to inhibit the mTOR pathway. One of the most consistently replicated lifespan-extension results in animal research.

Strong in animal models, human trials ongoing Pharmacological / repurposed drug

NAD+ Precursor Supplementation

Widely marketed NMN and NR supplements aim to restore age-related NAD+ decline. Animal data is strong; human trial results have been considerably weaker and more mixed.

Mixed / animal data stronger than human data Metabolic supplementation

Parabiosis-Inspired Plasma Therapies

Research into the young-blood factors behind parabiosis rejuvenation results is real and ongoing. Consumer plasma-infusion clinics selling the idea to the public are a separate, largely unproven story.

Early / largely unproven in humans Blood-factor / regenerative medicine

Senolytics

Drugs or compounds that selectively clear senescent cells that accumulate with age and drive chronic inflammation. Early human trials show safety and some biomarker effects.

Mixed / ongoing studies Senescent cell targeting

Stem Cell Therapy

Deploying stem cells or cell-derived factors to regenerate damaged tissue or restore declining cell populations. Highly indication-specific: some uses are clinically established, longevity applications are still investigational.

Varies by use case Regenerative medicine
Research publication: Evidence levels are noted per entry. This content is for educational purposes and does not constitute medical advice. Data reflects current research status and is updated as the field evolves.